Andrew Brack

2.6K posts

Andrew Brack

Andrew Brack

@BrackLab

Scientist interested in preventing functional decline during aging. Program Manager at ARPA-H. Interests: Crypto, Everton FC and Boxing. Views are my own.

CA Katılım Nisan 2012
1.1K Takip Edilen4.2K Takipçiler
Sabitlenmiş Tweet
Andrew Brack
Andrew Brack@BrackLab·
What if we had therapies to extend healthspan and prevent the onset of age related diseases? I’m excited to announce my first @ARPA_H program, PROSPR. The goal is to develop validated surrogate biomarkers, new clinical endpoints and therapies to collectively extend healthspan by 20 years for all Americans.
ARPA-H@ARPA_H

What if we could predict age-induced health issues before they happen? Our new PROSPR program aims to identify biochemical and physiological markers, paving the way for faster, more targeted aging research. arpa-h.gov/news-and-event…

English
17
33
167
34.3K
Andrew Brack retweetledi
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)
I did not have much room to breathe and write anything during or after #BIO2026 but you will see many stories from me covering BIO, LEAP, BioTaiwan, and WAIC that happened pretty much back-to-back. Here is my tribute to Australia and the roundtable that kicked-off the BIO2026 conference. It is very important country to explore for anyone in AI-powered drug discovery interested in saving 6 months to a year of development time. Check it out at Forever.AI: forever.ai/p/the-unsung-h…
Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) tweet media
English
2
7
20
1.6K
Maria Marinova, PhD
Maria Marinova, PhD@m__marinova·
Awesome work and great paper from Aaron and team but one issue with the science communication here. It didn’t reverse skin age for 70 to 31, it reversed levels of CML staining to less than those found in 31-year-old skin (as stated in the paper). They didn’t look at other aspects of skin aging.
The All-In Podcast@theallinpod

Friedberg: New study shows enzyme reverses skin age from 70+ years to 31 Chamath: That’s a $2T market. Did Scientists Just Discover How to Reverse Skin Aging!? “CML is kind of the predominant molecule that gets formed in this extracellular matrix that's driving aging, and nothing breaks it down. So these scientists set out to try and create an enzyme, an enzyme is a protein that breaks something down, that can break down CML. And so these guys kind of went out and they took the target, which is CML, and tried to figure out, ‘Okay, how do we actually degrade CML, clear that extracellular matrix, and reverse aging?’ They started to test it on the proteins that we would find in our body, casein, collagen, retinal proteins, which are in your eye, hemoglobin, and they were able to get rid of 52 to 97% of the CML, just degrade it away. And then they found several sites where they were able to degrade over 90%. And then they took actual human skin from elderly patients that had donated their skin, and they put this enzyme onto that skin, and they were able to eliminate 55% of the CML on the skin, basically reverse the skin's age down to the age of a 31-year-old, this is from greater than 70-year-old patients, just by putting this enzyme on the skin. And so it's kind of a groundbreaking demonstration of combination of AlphaFold, what's called directed evolution, where you change the order of the DNA that changes the structure of the protein to test different proteins, do high throughput screening, and ultimately make a novel protein that doesn't exist in nature today that can do something pretty profound for human health.” Chamath: “It will be a trillion-dollar market. If you can create a cream…” Friedberg: “I mean, dude, if you could put this enzyme literally on your skin and have it absorb in…” Chamath: “Game over. That alone is $2 trillion.”

English
4
7
36
2.3K
Jarod Rutledge
Jarod Rutledge@JarodRutledge1·
Lots of comments saying how impossible it is to solve aging with $1B. I disagree. With $1B of dedicated capital today, I too could solve aging. Better than @bryan_johnson. If you have $1B to invest in this purpose, I will happily walk you through exactly how.
Bryan Johnson@bryan_johnson

@MrBeast I'll take the billion and solve aging.

English
19
5
50
8.1K
Andrew Brack retweetledi
ARPA-H
ARPA-H@ARPA_H·
A cyberattack on a hospital isn’t just an IT issue — it’s a patient crisis. 642 cyber events. #1 targeted sector in 2025. Health care can't afford to wait. ARPA-H is fighting back with DIGIHEALS and UPGRADE. New Inside MedTech Innovation episode out now with Program Manager Andrew Carney. Listen here 👇 shannonlantzy.com/podcast/episod…
English
0
3
6
850
Andrew Brack retweetledi
Pearl Freier
Pearl Freier@PearlF·
It will be interesting to see/hear how biopharma companies & large pharma structure their deals with frontier labs. What protections are in place if an employee(s) leaves to start their own techbio/ AI x Bio company or drug development startup. "AI Sovereignty" $XBI
English
0
1
2
3.2K
Andrew Brack
Andrew Brack@BrackLab·
Yes. And that is what we have now. Single drug, single indication. But my hope/call out is that we move past that with geroscience-formed medicines that target the consequential loss of health/function. And that needs regulatory reform. Honestly, this is not easy and we are not there yet, but that’s where im placing my bets.
English
1
0
0
33
Alexander M. Wolf
Alexander M. Wolf@AlexanderMWolf7·
@BrackLab And any hypothetical anti-aging drug could also get approval for any age-related disease it postpones. If it, for example, prevents CVD like a statin, it can take the regulatory path of a statin. No?
English
1
0
0
19
Andrew Brack
Andrew Brack@BrackLab·
There is nothing more important than regulatory reform to bring treatments for aging to people. It is the conduit for a productive drug development industry.
The Alliance for Longevity Initiatives (A4LI)@theA4LI

Tomorrow, the @HouseCommerce Subcommittee on Health will examine how the @US_FDA can maintain America's leadership in biomedical innovation and strengthen U.S. drug development. Modernizing the regulatory framework is essential if we want to accelerate innovation, maintain our competitive edge in the biomedical sector, and ensure patients have access to the next generation of treatments. A4LI has submitted a letter for the hearing record urging Congress to consider our Multi-Disease Therapeutic Designation (MDTD) proposal: a regulatory pathway designed to better support therapies that target the underlying biology of aging and reduce the burden of multiple chronic diseases. 📄 Read our MDTD proposal here: a4li.org/wp-content/upl… We are thrilled to see Congress continuing this important conversation about the future of biomedical innovation, and we look forward to hearing expert perspectives on how the FDA can help foster this next generation of medical breakthroughs. ▶️ The full hearing can be livestreamed here: youtube.com/watch?v=sTL86n…

English
1
3
13
1.6K
Andrew Brack
Andrew Brack@BrackLab·
@AlexanderMWolf7 What did statins and glp1s get approval for? Indications with a regulatory path. And because of that many millions of people’s lives have benefitted.
English
1
0
0
19
Alexander M. Wolf
Alexander M. Wolf@AlexanderMWolf7·
@BrackLab I just doubt that "There is nothing more important than regulatory reform". Statins & GLP-1RAs made it. Any drug affecting aging can take the same prevention path, no? Regulatory reform, sure, but "most important"? A credible drug candidate would help, also with regulators.
English
1
0
0
23
Andrew Brack retweetledi
Aubrey de Grey
Aubrey de Grey@aubreydegrey·
HUGE breakthrough out today, in arguably the single most neglected aspect of aging, extracellular matrix damage. Top researchers have tried & failed for decades to do this. Massive kudos to Aaron and his team! (Proud to note that Revel is a SENS spinout.) revelpharmaceuticals.com/news
English
63
255
1.8K
523.9K
Andrew Brack
Andrew Brack@BrackLab·
bringing treatments to people and a productive drug development path requires a regulatory path. I dont make the rules. It’s just the way it works! As a former academic working in pre clinical models it took me a while to get my head around it. But my comment is not to be taken in isolation that pre clinical advances are not an important part of the drug pipeline.
English
1
0
0
31
Alexander M. Wolf
Alexander M. Wolf@AlexanderMWolf7·
@BrackLab Why not having a treatment first? Having a treatment that works in mice would be a very good argument for regulatory reform. Using animals first is not illegal. Unless, of course, you want to make money with things that don't really work.
English
1
0
0
40
Andrew Brack
Andrew Brack@BrackLab·
Important result from a cool @ARPA_H project. The IndiPHARM tool box will help explain non-uniform responses to a drug within a human population. Diabetes was the test case here. But I can see this being extended to age-related conditions.
ARPA-H@ARPA_H

A prescription shouldn’t be a guessing game. ARPA-H’s IndiPHARM uses one blood sample + AI-powered analysis to predict exactly how patients metabolize drugs. New research proves why this matters for diabetes. Read the paper. 👇 …ubs.pericles-prod.literatumonline.com/doi/10.1111/do… @ColumbiaMSPH @GaryWMiller3 @MayoClinic @EmoryUniversity @BrownUniversity @jacksonlab

English
0
3
9
1.1K
Mgoes (bio/acc 🤖💉)
Mgoes (bio/acc 🤖💉)@m_goes_distance·
THESIS UPDATE: I'm increasingly convinced the biggest signal in longevity right now isn't the science, it's what the FDA is willing to validate the FDA doesn't legally recognize aging as a disease. that's not a technicality, it's federal code. which means every longevity company, no matter how good the science, has to attach itself to a specific, narrowly defined condition just to get a regulatory pathway at all that's the actual filter separating real companies from good stories not "does the biology work" "did you find the disease that lets the FDA say yes" whoever solves that problem for the whole category, not just their own drug, changes everything downstream of it that's exactly the kind of infrastructure bet we're looking for still early, and open to being wrong here.
English
15
5
72
8.5K
Andrew Brack retweetledi
Karl Pfleger
Karl Pfleger@KarlPfleger·
Agree. A4LI lobbies for both. The multi-disease therapeutic designation (a4li.org/wp-content/upl…) will unlock more VC $ for biotech & trials. The disease burden framework for NIH funding (a4li.org/wp-content/upl…) will help fix the prob that basic science funding isn't aligned with disease burden to society. Write to your lawmakers in the House & Senate advocating for these proposals, explaining why aging is so bad but also feasible to treat, explaining that treatments for aging won't cause other problems in society (ref zenodo.org/records/188830… if you like), & encouraging the lawmaker to join the bipartisan Longevity Science Caucus, & to come to next year's A4LI H-Span summit. Dylan, Brenda, myself, & others are very happy to talk to lawmakers who are interested in knowing more or have questions.
English
0
1
2
171
Andrew Brack retweetledi
Alexey Strygin
Alexey Strygin@strygah·
I'm helping organize Mirai, a pop-up city running this October at KBIC (Kobe Biomedical Innovation Cluster), with a focus on longevity biotech, medical devices, and human augmentation. @aubreydegrey, @adamgries, @realNathanCheng, @EleanorSheekey, and @cremieuxrecueil have already confirmed their presence. More big names are still in talks (TBA). 🇯🇵Japan has built some of the world's fastest regulatory pathways for cell and gene therapies, and for adjacent biotech and medtech too. The Mirai program includes in-person meetings with local regulators, research institutes, and biopharma companies, plus intros to local partners. This is for you if: - you're looking for cofounders, partners, or a job in the field; - you want to bring your product to the Japanese market; - you're hunting for cutting-edge Japanese therapies for your own market; - you want to spend a month among smart people in a cool country and learn a ton. Early-bird tickets are cheap: $399 (and even cheaper with my promo code "ALEXEY"). It does not include housing or food, though. I've attended and helped organize several events like this (Zuzalu, @ZelarCity, Viva Frontier Tower). Every one has been a great experience, and I can't recommend it enough!! We also have a great value offering for sponsors. DM me if you want to know more.
Alexey Strygin tweet media
English
3
15
70
24.9K
Ira S. Pastor
Ira S. Pastor@irat1onal·
Where Did the "Moonshot" Go??? Remember when longevity conferences were full of slides about 150-year lifespans? when investors were told aging was the greatest opportunity in medical history? promises about pending "Longevity Escape Velocity?" Fast forward... Now we're celebrating regulatory pathways designed to measure whether an older adult can function a bit better. Again...That's valuable. It's also called GERIATRICS. Somewhere along the way, "curing aging" became "optimizing decline." That's a much smaller ambition...... @kaimicahmills @elimohamad
Longevity Technology@LongevityTech

Standard disease frameworks are meeting their match as pioneers lean on functional metrics and pragmatic stepping stone indications. vist.ly/5aq23 #longevity #geroscience #fda #clinicaltrials #regulation @ARPA_H @xprize

English
5
1
20
1.4K
Andrew Brack
Andrew Brack@BrackLab·
Strange argument…”average” IC drug that improves function without delaying disease progression will not become the next glp1. I agree with you. Low IC does correlate with increased disease incidence and increased mortality, so it could serve as a canary in the coal mine. If IC serves as a short term predictor of multimorbidity and or mortality it will absolutely be tested in clinical trials. As I said in my previous tweet, happy to hear your alternatives.
English
1
0
0
27
Ira S. Pastor
Ira S. Pastor@irat1onal·
I have no problem with IC - I think such drugs will be great for the QOL of the octogenarians and nonagenarians in my family. But: - I find it hard to believe the "average IC drug" that improves function without delaying disease progression will ever become the "next GLP-1"; and - IF a company is actually sitting on the a gero-therapeutic candidate that is the "next GLP-1" and possesses the properties to do what the gero-science hypothesis has been promising us the last couple decades (significantly delaying the chronic degenerative diseases that kill the majority of us) that an IC indication will be at the top of their strategic plan...
English
1
0
1
57
Alexey Strygin
Alexey Strygin@strygah·
Our longevity biotech deep dive for Social Capital crossed 350k views (way more than we anticipated). The full report is private. For investors looking at longevity biotech, here are two bets worth understanding: 1) The overcrowded bet: cellular reprogramming. Bezos, Altman, and Brian Armstrong went in early, and NewLimit just raised $435M from tier-1 VCs and Eli Lilly - a genuinely bullish signal. Still, only two studies show a lifespan gain in normal mice (7-12%), so don't expect systemic rejuvenation from the first generation of epigenetic reprogramming therapies, but they'll very likely show efficacy against specific diseases. It might not be too late to enter the field, but it's definitely not early: three companies with only preclinical data are already at unicorn valuations. 2) The asymmetric bet: growing and preserving organs. Today up to 75% of donated hearts and lungs are wasted because they last only hours outside the body, and globally just ~10% of the need is met. The companies fixing that, building new organ sources and learning to bank them long-term, are early, and many are still in stealth. We personally know who's building what, and it's still possible to get in at low valuations. That's where the alpha is hidden. For the @chamath's @socialcapital deep dive, we assembled a group of 17 leading scientists, founders, and experts. Much of the useful signal is offline: who’s building in stealth, which founders can actually deliver, and which science is real versus merely well-promoted. With that work finished, we now have capacity for the next longevity biotech project for a family office, fund, private banking team, or private investor looking at the field. Beyond deep dives, we can help you source stealth deals, run due diligence, build custom intel tools, or launch client-facing longevity products. Know someone who runs a family office or fund and is into longevity? Share this with them. Want details? Let's jump on a quick call - DM.
Alexey Strygin tweet media
English
11
16
67
3.6K
Nathan of Pennsylvania
Nathan of Pennsylvania@JerichoSionNat·
@KarlPfleger @irat1onal Insufficient funding remains a major problem. Not even a fraction of one percent of GDP is allocated to fundamental research that could bring about significant breakthroughs.
English
1
0
0
60